Loading your page…
Marketing-authorisation holder
1 medicine in 1 country, as authorisation holder and marketer.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine in the registers under its name, current ones first.
1 medicine
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| HANSATERM 4,8 MG APÓSITO ADHESIVO MEDICAMENTOSO4,8 mg · Apósito adhesivo medicamentoso | Capsaicin | Spain | Marketed | 2004 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of Canada
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Report an error or request removalCorrections from the company itself are welcome.
